CD8A and neoplasm: A multicenter phase 1 clinical trial for PEGylated IL-10 monotherapy and combination therapy with anti-PD-1 also demonstrated expansion of antigen experienced CD8+ T cells in advanced tumor patients in both groups, further supporting an activating role for IL-10 in tumor immunity (128).